Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum
- 28 September 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (13) , E1334-E1342
Abstract
Objective: To investigate the association of age and the presence of contrast enhancing lesions (CELs) on cranial MRI scans in different disease courses of multiple sclerosis (MS), we describe the frequency of CELs as a function of age in four large randomized controlled trial (RCT) datasets. Methods: Using original trial data from CombiRx (clinicaltrials.gov identifier NCT00211887), a trial in relapsing-remitting MS, ASCEND (NCT01416181) a trial in secondary progressive MS, and the two primary progressive MS trials PROMISE and INFORMS (NCT00731692), we describe the occurrence of CELs per age group at baseline for the entire trial cohort, and at one year follow-up in the treatment arms. Results: CombiRx included 1,008, ASCEND 889, PROMISE 943, and INFORMS 970 participants. At baseline, CEL frequency differed between datasets according to disease courses: 39.6% of CombiRx, 23.9% of ASCEND, 14.0% of PROMISE, and 12.3% of INFORMS participants had CELs. This distribution by disease course was largely preserved within each age group. In all datasets, there was an almost linear decrease of the percentage of participants with CELs with advancing age. After one year of experimental treatment, CEL occurrence was reduced in all trial datasets, and almost absent in ASCEND. The decrease of CEL occurrence with advancing age was preserved in CombiRx, PROMISE and INFORMS after one year of treatment. We investigated the association of the baseline factors age, disease duration, sex and EDSS with having CELs at baseline with multivariable binary logistic regression models. Age was the only characteristic associated with the risk of CELs at baseline in all datasets, with higher age associated with a lower risk of CELs (odds ratios (OR) for having CELs at baseline per year increase in age: CombiRx: 0.96, 95% confidence interval (CI) 0.95 to 0.98, ASCEND: 0.94, 95% CI 0.92 to 0.97, PROMISE: OR 0.94, 95% CI 0.91 to 0.96, INFORMS: 0.97 95% CI 0.94 to 0.99). Conclusions: Our analysis of four large, well-characterized RCT datasets shows that the association of age and CEL occurrence is a general phenomenon across the spectrum of MS disease courses. Our findings should be replicated in real world MS datasets.Keywords
This publication has 20 references indexed in Scilit:
- Progressive multiple sclerosis: pathology and pathogenesisNature Reviews Neurology, 2012
- Will the real multiple sclerosis please stand up?Nature Reviews Neuroscience, 2012
- A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosisJournal of Neurology, 2008
- Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trialAnnals of Neurology, 2007
- Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosisJournal of the Neurological Sciences, 2005
- Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trialsNeurology, 2005
- Is inflammation important in early PPMS? a longitudinal MRI studyJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Linomide in relapsing and secondary progressive MSNeurology, 2000
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983